Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alimera Sciences Inc ALIM

Healthcare
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye ... see more

Recent & Breaking News (NDAQ:ALIM)

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 20, 2024

Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

GlobeNewswire March 19, 2024

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

GlobeNewswire March 7, 2024

Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update

GlobeNewswire February 29, 2024

The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®

GlobeNewswire February 8, 2024

Alimera Completes Recruitment for the Synchronicity Study

GlobeNewswire January 4, 2024

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 2, 2024

Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 12, 2023

Alimera Appoints Maggie A. Pax to Its Board of Directors

GlobeNewswire November 8, 2023

Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology

GlobeNewswire October 31, 2023

Alimera Sciences Reports Third Quarter 2023 Results

GlobeNewswire October 26, 2023

Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update

GlobeNewswire October 16, 2023

Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress

GlobeNewswire October 11, 2023

Alimera Sciences Appoints Jason Werner as Chief Operating Officer

GlobeNewswire October 3, 2023

Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 5, 2023

Alimera Sciences Reports Second Quarter 2023 Results

GlobeNewswire August 10, 2023

Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline

Newsfile August 8, 2023

Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update

GlobeNewswire August 2, 2023

Alimera Completes Recruitment for its Landmark NEW DAY Study

GlobeNewswire May 24, 2023

Alimera Acquires U.S. Commercial Rights to YUTIQ®

GlobeNewswire May 18, 2023